Physician profile

Andrew White

Family Medicine · Winchester, VA

NPI 1255310686

$474.86

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$289.30

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $98.13 2021-2022
Amgen INC. $87.43 2019
Neurocrine Biosciences, INC. $60.38 2023-2024 Ingrezza
Corium, LLC $52.76 2024 Azstarys
Teva Pharmaceuticals USA, INC. $50.85 2024 Uzedy, Austedo Xr
Abbvie INC. $43.81 2023-2024 Vraylar
Alkermes, INC. $35.45 2024 Aristada, Lybalvi
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $25.09 2024 Caplyta
Lundbeck LLC $20.96 2024 Rexulti

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew White

$474.86

in general payments reported 2019-2025

Years
2019-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/939797/andrew-white

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.